These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29361475)

  • 21. Surgical outcome of laparoscopic surgery, including laparoendoscopic single-site surgery, for retroperitoneal paraganglioma compared with adrenal pheochromocytoma.
    Hattori S; Miyajima A; Hirasawa Y; Kikuchi E; Kurihara I; Miyashita K; Shibata H; Nakagawa K; Oya M
    J Endourol; 2014 Jun; 28(6):686-92. PubMed ID: 24499341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary gland pleomorphic adenoma in the Netherlands: A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence.
    Valstar MH; de Ridder M; van den Broek EC; Stuiver MM; van Dijk BAC; van Velthuysen MLF; Balm AJM; Smeele LE
    Oral Oncol; 2017 Mar; 66():93-99. PubMed ID: 28249655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
    Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
    Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.
    Beard CM; Sheps SG; Kurland LT; Carney JA; Lie JT
    Mayo Clin Proc; 1983 Dec; 58(12):802-4. PubMed ID: 6645626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data.
    Stenström G; Svärdsudd K
    Acta Med Scand; 1986; 220(3):225-32. PubMed ID: 3776697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
    Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.
    Lee SE; Oh E; Lee B; Kim YJ; Oh DY; Jung K; Choi JS; Kim J; Kim SJ; Yang JW; An J; Oh YL; Choi YL
    Oncotarget; 2016 Apr; 7(17):24141-53. PubMed ID: 27007161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pheochromocytoma and paraganglioma in Fontan patients: Common more than expected.
    Song MK; Kim GB; Bae EJ; Lee YA; Kim HY; Min SK; Kim JH; Won JK
    Congenit Heart Dis; 2018 Jul; 13(4):608-616. PubMed ID: 30033572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
    Burnichon N; Cascón A; Schiavi F; Morales NP; Comino-Méndez I; Abermil N; Inglada-Pérez L; de Cubas AA; Amar L; Barontini M; de Quirós SB; Bertherat J; Bignon YJ; Blok MJ; Bobisse S; Borrego S; Castellano M; Chanson P; Chiara MD; Corssmit EP; Giacchè M; de Krijger RR; Ercolino T; Girerd X; Gómez-García EB; Gómez-Graña A; Guilhem I; Hes FJ; Honrado E; Korpershoek E; Lenders JW; Letón R; Mensenkamp AR; Merlo A; Mori L; Murat A; Pierre P; Plouin PF; Prodanov T; Quesada-Charneco M; Qin N; Rapizzi E; Raymond V; Reisch N; Roncador G; Ruiz-Ferrer M; Schillo F; Stegmann AP; Suarez C; Taschin E; Timmers HJ; Tops CM; Urioste M; Beuschlein F; Pacak K; Mannelli M; Dahia PL; Opocher G; Eisenhofer G; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2012 May; 18(10):2828-37. PubMed ID: 22452945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of pheochromocytoma in South Galicia, Spain.
    Fernández-Calvet L; García-Mayor RV
    J Intern Med; 1994 Dec; 236(6):675-7. PubMed ID: 7989903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.
    Opotowsky AR; Moko LE; Ginns J; Rosenbaum M; Greutmann M; Aboulhosn J; Hageman A; Kim Y; Deng LX; Grewal J; Zaidi AN; Almansoori G; Oechslin E; Earing M; Landzberg MJ; Singh MN; Wu F; Vaidya A
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1325-34. PubMed ID: 25581599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series.
    Oudijk L; de Krijger RR; Rapa I; Beuschlein F; de Cubas AA; Dei Tos AP; Dinjens WN; Korpershoek E; Mancikova V; Mannelli M; Papotti M; Vatrano S; Robledo M; Volante M
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1376-80. PubMed ID: 24684458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis.
    Amar L; Lussey-Lepoutre C; Lenders JW; Djadi-Prat J; Plouin PF; Steichen O
    Eur J Endocrinol; 2016 Oct; 175(4):R135-45. PubMed ID: 27080352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA.
    Suh YJ; Choe JY; Park HJ
    Endocr Pathol; 2017 Jun; 28(2):159-164. PubMed ID: 28386672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pheochromocytoma in Africa: rarity, gravity and ectopy].
    Sidibe EH
    Ann Urol (Paris); 2001 Jan; 35(1):17-21. PubMed ID: 11233314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics of pheochromocytoma and paraganglioma in Spanish patients.
    Cascón A; Pita G; Burnichon N; Landa I; López-Jiménez E; Montero-Conde C; Leskelä S; Leandro-García LJ; Letón R; Rodríguez-Antona C; Díaz JA; López-Vidriero E; González-Neira A; Velasco A; Matias-Guiu X; Gimenez-Roqueplo AP; Robledo M
    J Clin Endocrinol Metab; 2009 May; 94(5):1701-5. PubMed ID: 19258401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer Incidence in Kerman Province, Southeast of Iran: Report of an ongoing Population-Based Cancer Registry, 2014.
    Shahesmaeili A; Malekpour Afshar R; Sadeghi A; Bazrafshan A
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1533-1541. PubMed ID: 29936728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.